Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 05 2022 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 Form
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange
Act of 1934 July 2022
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into
English)
75/76 Wimpole Street London
W1G 9RT United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F o
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ___________
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ___________
CONTENTS
On June
30, 2022, an Annual General Meeting of Shareholders of Akari Therapeutics, Plc (the “Company”) was held. At the meeting,
all proposals brought before the Company’s shareholders were approved in accordance with the majority required for each
proposal. Each of those proposals was described in the Company’s Notice of Annual General Meeting of Shareholders, dated June
6, 2022, and in its Proxy Statement, dated June 6, 2022, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished
to the U.S. Securities and Exchange Commission on June 6, 2022.
The information contained in this
report is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of
1933.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Akari Therapeutics, Plc |
|
(Registrant) |
|
|
|
By: |
/s/ Rachelle Jacques |
|
|
Name:
Title: |
Rachelle Jacques President and Chief Executive Officer |
Date:
July 5, 2022
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024